Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

Key facts

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Principal Investigator

Janelle Perkins, PharmD

H. Lee Moffitt Cancer Center and Research Institute

Intervention

Tac+MTX(drug)

Enrollment

89 enrolled

Eligibility

All sexes

Timeline

2005 – 2011

Study locations (1)

• H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare disorder potentially indicated for transplant or complication after transplantation

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT04886726
  PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
  Henry Ford Health System
• RECRUITINGPHASE2, PHASE3NCT03818334
  Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
  Hospital Israelita Albert Einstein

See all trials for Rare disorder potentially indicated for transplant or complication after transplantation →